共查询到20条相似文献,搜索用时 62 毫秒
1.
2.
3.
“八五”科技攻关项目“食管癌高发现场综合防治研究”,经专家评审,国家科委正式批准,确定河北省磁县为食管癌综合防治研究现场,为切实加强此项工作的领导,确保这一重大课题的顺利进行,经国家、省、地、县有关部门研究决定,成立“河北省磁县食管癌防治研究领导小组”。 1992年5月8日,在磁县隆重召开了成立大会。全国肿瘤防治研究办公室主任李连弟,河北省卫生厅副厅长陈巽昭,磁县人民政府县长丁俊 相似文献
4.
《抗癌之窗》2006,(4)
河南省林县是我国乃至世界上食管癌发病率最高的地区之一。上个世纪60年代初,根据周总理指示,中国医学科学院肿瘤研究所肿瘤医院的医务工作者就开始致力于林县食管癌的防治研究工作,坚持至今,取得了丰硕的研究成果。林县食管癌的综合防治工作始终采取了领导、专家、群众相结合;现场、实验室、临床相结合;早诊、早治、预防相结合;中西医相结合,从现场实际情况出发为基本工作方法,开展了广泛的研究和防治工作,走出了一条符合我国特色的肿瘤预防控制之路。食管癌高发现场综合防治研究被评为1995年全国十大科技成果之一。在多年坚持不懈的科学防治下,当地食管癌发病率、死亡率明显下降,从另一个侧面反映了癌症综合防治的良好效果。 相似文献
5.
食管癌的综合防治研究进展 总被引:6,自引:1,他引:5
中国食管癌死亡率世界最高,又以河南、河北。山西交界处的太行山南部地区的死亡率最高。自1972年开始,中国医学科学院肿瘤研究所肿瘤医院,先后在河南林县和河北磁县食管癌高发现场,采取现场与实验室相结合,基础与临床相结合的方法,进行了全面、系统、多学科综合防治食管癌的研究,以探索一条符合中国国情的食管癌综合防治之路。本文主要介绍我国食管癌综合防治方面的进展。回病因与癌变机理的研究食管癌的发生发展是一个多因素。多阶段、多基因参与的复杂过程。我国在食管癌病因学方面,研究了炎症、真菌、病毒、亚硝胺及其前体物、营… 相似文献
6.
由中国医学科学院肿瘤研究所、河北医学院、河北省肿瘤医院、省肿瘤研究所和磁县共同承担的国家“八五”科技攻关项目“食管癌高发现场综合预防研究”汇报会,于1991年11月28日至12月4日在石家庄市召开。该项目确定河北省磁县为食管癌高发研究现场,河北省政协、省科委、卫生厅、磁县人民政府等有关方面领导出席了会议,全国肿瘤防治研究办公室李连弟主任到会并讲了话。会议期 相似文献
7.
8.
9.
10.
近期 ,淮安市科委组织邀请了江苏省、市近10位相关专家 ,对楚州区(原淮安市)肿瘤防治办公室、卫生防疫站主持实施的社会发展项目“淮安市‘国家食管癌防治研究现场’的建立与发展研究”进行了鉴定。楚州区(原淮安市)从1986年以来经过为期15年的探索研究 ,在食管癌综合防治现场的建设过程中开展了大量的工作及研究。该项目借鉴国内肿瘤高发现场防治经验 ,立足当地实际 ,利用现有卫生防疫网 ,实施“一网多用” ,形成社区肿瘤综合防治体系 ,并以“以防引研、以研促防、防研互补”运行机制 ,引入科研院所开展肿瘤科研课题的协作 ,完… 相似文献
11.
Vincent Grégoire Mererid Evans Quynh-Thu Le Jean Bourhis Volker Budach Amy Chen Abraham Eisbruch Mei Feng Jordi Giralt Tejpal Gupta Marc Hamoir Juliana K. Helito Chaosu Hu Keith Hunter Jorgen Johansen Johannes Kaanders Sarbani Ghosh Laskar Anne Lee Cai Grau 《Radiotherapy and oncology》2018,126(1):3-24
12.
13.
Selenium, lycopene, alpha-tocopherol, beta-carotene, retinol, and subsequent bladder cancer 总被引:5,自引:0,他引:5
To examine the association between serum nutrients and the development of bladder cancer we measured selenium, alpha-tocopherol, lycopene, beta-carotene, retinol, and retinol-binding protein in serum collected from 25,802 persons in Washington County, MD, in 1974. Serum samples were kept frozen at -70 degrees C. In the subsequent 12-year period, 35 cases of bladder cancer developed among participants. Comparisons of serum levels in 1974 among cases and two matched controls for each case showed that selenium was significantly lower among cases than controls (P = 0.03), lycopene was lower among cases at a borderline level of significance (P = 0.07), and alpha-tocopherol was nonsignificantly lower (P = 0.13). For selenium there was a nearly linear increase in risk with decreasing serum levels (P = 0.03). When examined by tertiles, the odds ratio associated with the lowest tertile of selenium compared to the highest tertile was 2.06. Serum levels of retinol, retinol-binding protein, and beta-carotene were similar among cases and controls. These results support a role for selenium in the prevention of bladder cancer. 相似文献
14.
《Lung cancer (Amsterdam, Netherlands)》1994,10(5-6)
15.
16.
目的 探讨80岁以上合并肠梗阻的结直肠癌患者的外科治疗策略。方法 回顾性分析中国医学科学院结直肠外科2007年1月—2018年12月行结直肠癌手术且术前合并肠梗阻的77例80岁以上患者的临床病理资料,按照手术方式分为根治组(n=58)与非根治组(n=19),比较两组患者临床病理特征、围手术期相关指标和预后。采用Kaplan-Meier法进行生存分析,Log rank检验进行生存时间比较;应用Cox比例风险模型进行多因素分析,对影响预后的因素进行分析。结果 根治组TNM分期为Ⅳ期患者的比例明显低于非根治组(8.6% vs. 57.9%, P<0.001)。根治组患者的5年生存率明显高于非根治组(65.5% vs. 26.3%, P<0.001)。单因素分析显示TNM分期和是否行根治性手术与合并肠梗阻的老年结直肠癌患者预后相关。多因素分析表明是否行根治性手术是影响80岁以上合并肠梗阻的结直肠癌患者预后的独立因素。结论 是否行根治性手术是影响80岁以上合并肠梗阻的结直肠癌患者预后的独立因素。 相似文献
17.
B Barlogie W S Velasquez R Alexanian F Cabanillas 《Journal of clinical oncology》1989,7(10):1514-1517
Based on remarkable activity in refractory lymphomas, a combination of etoposide, cisplatin (both administered by 4-day continuous infusions), cytarabine (Ara-C), and dexamethasone (EDAP) was evaluated in 20 patients with advanced myeloma refractory to standard melphalan and prednisone (MP) and/or vincristine, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and dexamethasone (VAD) and even to high doses of melphalan (HDM) (seven patients). Forty percent of patients responded regardless of previously recognized risk factors (eg, duration of drug resistance, tumor mass, and serum lactic dehydrogenase [LDH] level). While the median survival was only 4.5 months, patients with good performance (Zubrod less than 2) and low or intermediate tumor stage survived more than 14 months compared with only 2 months for the remaining group. EDAP could be readily administered in the outpatient clinic, but neutropenic fever prompted hospital admission in 80% of patients, half of whom developed penumonia and sepsis, a fatal outcome in four patients. Severe myelosuppression was of short duration, so that subsequent cycles could be administered every 3 to 4 weeks. No serious extramedullary toxicity, including renal toxicity, was encountered. Marrow toxicity and hence infectious complications may be reduced by elimination of Ara-C without compromising treatment efficacy. We conclude that the lack of cross-resistance with VAD and even HDM makes EDAP or a similar combination an attractive regiment to be formally explored in an alternating sequence with VAD in high-risk myeloma. 相似文献
18.
The in vitro activity of tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin was tested against 63 clinical isolates of Ureaplasma urealyticum. The minimal inhibitory concentrations (MICs) and the minimal bactericidal concentrations (MBCs) were determined by the broth microdilution method in A7 medium. The MIC(50) and MIC(90) of the tested agents after 24 h of incubation were as follows: tetracycline, 0.5 and 2.0 μg/ml; doxycycline, 0.125 and 0.25 μg/ml; erythromycin, 2.0 and 8.0 μg/ml; roxithromycin, 2.0 and 4.0 μg/ml; clarithromycin, 0.25 and 1.0 μg/ml; azithromycin, 2.0 and 4.0 μg/ml; levofloxacin, 1.0 and 2.0 μg/ml; and moxifloxacin, 0.5 and 0.5 μg/ml, respectively. The MIC values after 24 h and 48 h incubation differed by no more than one dilution for all the agents with the exception of doxycycline (two dilution difference for MIC(90)). Overall, moxifloxacin was the most active agent in vitro against U. urealyticum, with the narrowest difference between MIC and MBC values, followed closely by levofloxacin. Clarithromycin was the most active macrolide. 相似文献
19.
《Journal of chemotherapy (Florence, Italy)》2013,25(2):77-79
AbstractThe in vitro activity of tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin was tested against 63 clinical isolates of Ureaplasma urealyticum. The minimal inhibitory concentrations (MICs) and the minimal bactericidal concentrations (MBCs) were determined by the broth microdilution method in A7 medium. The miC50 and miC90 of the tested agents after 24 h of incubation were as follows: Tetracycline, 0.5 and 2.0 μg/ml; doxycycline, 0.125 and 0.25 μg/ml; erythromycin, 2.0 and 8.0 μg/ml; roxithromycin, 2.0 and 4.0 μg/ml; clarithromycin, 0.25 and 1.0 μg/ml; azithromycin, 2.0 and 4.0 μg/ml; levofloxacin, 1.0 and 2.0 μg/ml; and moxifloxacin, 0.5 and 0.5 μg/ml, respectively. The MIC values after 24 h and 48 h incubation differed by no more than one dilution for all the agents with the exception of doxycycline (two dilution difference for MIC90). Overall, moxifloxacin was the most active agent in vitro against U. Urealyticum, with the narrowest difference between MIC and MBC values, followed closely by levofloxacin. Clarithromycin was the most active macrolide. 相似文献
20.